Articles on risk benefit and drug discovery include:

Warren JB. Unbalanced risk-benefit analysis of ADHD drugs. Lancet Psychiatry 2018;5:871.

Warren JB. Meta-analysis of antidepressants. Lancet 2018;390:1010-1011.

Dimmitt SB, Stampfer HG, Martin JH, Warren JB. Clinical benefits of evolocumab appear less than hoped. Lancet 2018;391:934-5.

Dimmitt S, Stamfer, Martin JH, Warren JB. The pharmacodynamic and clinicl trial evidence for statin dose. BJCP 2018;84:1128-35.

Warren JB. Fatal prescription charts. BJCP 2018;84:417-8.

Floyd C, Warren JB. Opiates out of control. BJCP 2017;83:221-223.

Warren JB. Composite endpoints and the distortion of risk benefit analysis. BJCP 2017;83:221–223

Warren JB, Dimmitt S, Stampfer H. Cholesterol trials and mortality. BJCP 2016;82:168-177.

Dimmitt SB, Moran A, Scartozzi M, Stampfer HG, Warren JB. Excessive range of statin dose in W. Australian primary care. Int Med J 2015;45:860-863.

Dimmitt SB, Warren JB, Martin JH, Stampfer HG. Trading lower HbA1c for increased adverse events - a zero sum game? JACC 2016;68:1372-3.

Dimmitt S, Stampfer H, Warren J. Common statin side effects explain poor compliance. BJCP 2015;80:17.

Dimmitt SB, Stampfer HG, Moran A, Scartozzi M, Warren JB. Statin dose based on limited evidence. JACC 2015;65:759-60.

Dimmitt S, Stampfer H, Warren J. Beta blockers valuable but higher doses not necessary. BJCP 2014;78;1076–1079.

Warren JB, Day S, Feldschreiber P. Symmetrical analysis of risk-benefit. BJCP 2013;74:757-761.

Warren JB. Generics, chemisimilars and biosimilars: is clinical testing fit for purpose? BJCP 2012;75:7-14.

Warren JB. Antidepressants and the developing nervous system. BJCP 2012;73:1-3.

Warren J. Drug Discovery: Lessons from Evolution. BJCP 2011;71:497-503.

Warren JB, Oselin K. Comment: Generics and therapeutic substituion: BJCP 2011, 72:733-34.

Ritter JM, Harding I, Warren JB. Precaution, cyclooxygenase inhibition, and cardiovascular risk.TIPS 2009;30:503-8.

Mackay A, Warren JB. Responsibility for lack of psychopharmacological innovation. Lancet 2009;374:290

Warren JB. The Regulatory Process: Pharmacovigilance in Practice. (chapter) The Law and Regulation of Medicines. OUP, 2008.

Earlier publications include:

FASEB Journal   1993;7:1394-1400;  1994;8:247-251;  1995:9:411-418;  

Am J Physiology 1992;263:H1963-1966;   1993;265:H176-182;   1994;266:H1846-1853;   1998;275:H1388-1394;

Clinical Science  1983; 64:475-479;   1984; 66:79-85;   1984; 66:47-51.

 

Medicines Assessment is a UK limited company, no. 07367226

 

 

About us

P1040437

John Warren is a clinical scientist with wide experience in pharmacology, clinical pharmacology and medicines regulation.

 

   •Member of the European Scientific Advice Working Party 2003 -2010

   •Expert Medical Assessor, UK Medicines Healthcare products Regulatory Agency 1995 to 2010

   •Evaluated New Drug Applications, Clinical Trials, Generics and Variations for UK and Europe

   •Member of the European Pharmacokinetic Subgroup of the Efficacy Working Party 2007-8

   •Member of the writing committee of the Bioequivalence EU Notes for Guidance, released 2009

   •Contributed to the EU Notes for Guidance on Asthma, COPD and ARDS

   •Specialist accreditation in the UK in General Medicine, Clinical Pharmacology and Cardiology  

   •Author of over 100 publications in international journals on the physiology and pharmacology of

           the autonomic system. Edited book - "The Endothelium"

   •Executive Editor for British Journal of Clinical Pharmacology. Past member of the Editorial Board

           of Microvascular Research and Clinical Pharmacology & Therapeutics

 

Previous appointments include Clinical Pharmacology at the Royal Postgraduate Medical School and Senior Lecturer at the National Heart and Lung Institute, with Honorary Consultant status at the Brompton, Charing Cross and Chelsea & Westminster Hospitals.